X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1523) 1523
Book Review (139) 139
Publication (59) 59
Conference Proceeding (24) 24
Newsletter (21) 21
Newspaper Article (11) 11
Book Chapter (4) 4
Magazine Article (4) 4
Web Resource (4) 4
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nebivolol (1432) 1432
index medicus (867) 867
humans (672) 672
male (522) 522
hypertension (413) 413
female (398) 398
benzopyrans - therapeutic use (345) 345
ethanolamines - therapeutic use (345) 345
hypertension - drug therapy (326) 326
middle aged (316) 316
ethanolamines - pharmacology (300) 300
benzopyrans - pharmacology (299) 299
cardiac & cardiovascular systems (297) 297
pharmacology & pharmacy (295) 295
adrenergic beta-antagonists - therapeutic use (275) 275
animals (262) 262
blood pressure - drug effects (233) 233
adrenergic beta-antagonists - pharmacology (219) 219
nitric oxide (216) 216
aged (206) 206
treatment outcome (206) 206
adult (200) 200
peripheral vascular disease (194) 194
antihypertensive agents - therapeutic use (189) 189
carvedilol (173) 173
atenolol (172) 172
rats (171) 171
beta-blockers (160) 160
metoprolol (154) 154
nitric-oxide (145) 145
hypertension - physiopathology (143) 143
benzopyrans - administration & dosage (139) 139
ethanolamines - administration & dosage (139) 139
heart failure (132) 132
oxidative stress (128) 128
blood-pressure (122) 122
heart rate - drug effects (115) 115
heart failure - drug therapy (110) 110
double-blind method (106) 106
mortality (104) 104
endothelium, vascular - drug effects (103) 103
dose-response relationship, drug (101) 101
beta-blocker (99) 99
endothelial dysfunction (99) 99
nitric oxide - metabolism (99) 99
antihypertensive agents - pharmacology (92) 92
vasodilator agents - pharmacology (87) 87
benzopyrans - adverse effects (84) 84
ethanolamines - adverse effects (84) 84
vasodilation - drug effects (84) 84
adrenergic beta-antagonists - administration & dosage (78) 78
time factors (78) 78
antihypertensive agents - administration & dosage (77) 77
vasodilator agents - therapeutic use (77) 77
blood pressure (75) 75
drug therapy (72) 72
heart-failure (72) 72
cardiovascular (67) 67
essential-hypertension (67) 67
adrenergic beta-antagonists - adverse effects (66) 66
medicine, general & internal (66) 66
double-blind (65) 65
prospective studies (63) 63
abridged index medicus (62) 62
dosage and administration (61) 61
analysis (60) 60
drug therapy, combination (60) 60
endothelium (60) 60
research (60) 60
dysfunction (59) 59
nitric-oxide synthase (58) 58
antihypertensive agents - adverse effects (57) 57
medicine & public health (57) 57
metoprolol - therapeutic use (56) 56
nebivolol hydrochloride (56) 56
oxidative stress - drug effects (56) 56
endothelial-cells (55) 55
hypertension - complications (55) 55
internal medicine (55) 55
arterial hypertension (54) 54
care and treatment (54) 54
rats, wistar (53) 53
adrenergic beta-1 receptor antagonists - therapeutic use (52) 52
hemodynamics - drug effects (52) 52
propanolamines - therapeutic use (52) 52
valsartan (52) 52
β-blockers (52) 52
carbazoles - therapeutic use (51) 51
aged, 80 and over (50) 50
cardiology (49) 49
heart failure - physiopathology (49) 49
therapy (49) 49
forearm vasculature (48) 48
bisoprolol (47) 47
elderly-patients (47) 47
endothelium, vascular - physiopathology (46) 46
follow-up studies (46) 46
mechanisms (46) 46
nebivolol - therapeutic use (46) 46
nitric-oxide release (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1348) 1348
Russian (122) 122
German (46) 46
French (14) 14
Turkish (12) 12
Spanish (8) 8
Hungarian (7) 7
Italian (5) 5
Polish (4) 4
Romanian (3) 3
Korean (2) 2
Portuguese (2) 2
Ukrainian (2) 2
Chinese (1) 1
Croatian (1) 1
Japanese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


10/2011
Objectives: To study the effect of nebivolol 5 mg once daily versus (S)-atenolol 25 mg once daily in patients with essential hypertension. Materials and... 
Essential hypertension | nebivolol | (S)-atenolol
Web Resource
Journal of Organic Chemistry, ISSN 0022-3263, 04/2015, Volume 80, Issue 8, pp. 3965 - 3973
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2005, Volume 26, Issue 3, pp. 215 - 225
Aims Large randomized trials have shown that beta-Mockers reduce mortality and hospital admissions in patients with heart failure. The effects of beta-blockers... 
Heart failure | Nebivolol | Randomized trial | Elderly | Beta-blocker | Ejection fraction
Journal Article
10/2011
Background: Nebivolol is a third-generation β-blocker, with highest β1 selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative... 
nebivolol | lipid profile | blood sugar | Atenolol
Web Resource
British Journal of Clinical Pharmacology, ISSN 0306-5251, 07/2016, Volume 82, Issue 1, pp. 83 - 91
Journal Article
Journal Article
Journal Article
07/2009
Nebivolol is a β-blocker that is highly selective for β1-adrenergic receptors with vasodilating properties. This property can be attributed to an endothelial... 
Nebivolol | Nitric oxide | Osteoporosis treatment | Anti-oxidant action
Web Resource
JOURNAL OF HYPERTENSION, ISSN 0263-6352, 10/2018, Volume 36, pp. E229 - E229
Conference Proceeding
British Journal of Pharmacology, ISSN 0007-1188, 04/2006, Volume 147, Issue 7, pp. 699 - 706
Journal Article
Drugs, ISSN 0012-6667, 2007, Volume 67, Issue 8, pp. 1097 - 1107
β-Adrenoceptor antagonists (β-blockers) have historically been considered an effective and safe option for first-line treatment of hypertension. However, very... 
Nebivolol | Hypertension
Journal Article
Journal Article
Asian Journal of Chemistry, ISSN 0970-7077, 04/2016, Volume 28, Issue 4, pp. 811 - 813
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.